Sandy Hutchens Cancer Prevention

Pomegranates and Phytochemicals, Cancer Beware!

Eating a pomegranate everyday can help prevent breast cancer, new research reveals. American scientists are saying pomegranates contain chemical agents known as phytochemicals, which play an important role in the prevention of breast cancer.

Scientists at the City of Hope Cancer Research and Treatment Center in Duarte, California, have discovered that the fruit contains a large amount of the phytochemical called ellagitannins. The phytochemical has an inhibitory effect on the enzyme aromatase, which plays a pivotal role in making the hormone oestrogen, which in turn leads to most of the cases of breast cancer. Meanwhile, many patients who suffer from the breast cancer take medicines which are actually aromatase inhibitors.

The research which was published in the journal ‘Cancer Prevention Research’ highlights the fact that laboratory experiments that were carried out took into account around 10 compounds from the pomegranate and their effects were subsequently tested. Among the compounds which were taken into consideration, urolithin B was seen to be the most effective in preventing breast cancer.

However, researcher Shiuan Chen, who was intrinsically involved with the research, emphasized that the compounds did not turn out to be as effective as actual drugs due to which researchers have warned the patients against using the fruit as a replacement of the aromatase inhibitor medicines. At the same time, it has been implied that the results are not conclusive and further tests need to be carried out in order to confirm the findings. However, the findings are being considered to be significant as it might herald a new era in breast cancer treatment.

Read more: Pomegranates and Cancer.

Chinese Medicine Drug May Treat Cancer

A promising cancer drug, first discovered in a mushroom commonly used in Chinese medicine, could be made more effective thanks to researchers who have discovered how the drug works. The research is funded by the Biotechnology and Biological Sciences Research Council and was carried out at The University of Nottingham.

In research to be published in the Journal of Biological Chemistry, Dr Cornelia de Moor of The University of Nottingham and her team have investigated a drug called cordycepin, which was originally extracted from a rare kind of wild mushroom called cordyceps and is now prepared from a cultivated form.

Dr de Moor said: “Our discovery will open up the possibility of investigating the range of different cancers that could be treated with cordycepin. We have also developed a very effective method that can be used to test new, more efficient or more stable versions of the drug in the Petri dish. This is a great advantage as it will allow us to rule out any non-runners before anyone considers testing them in animals.”

Cordyceps is a strange parasitic mushroom that grows on caterpillars (see image). Properties attributed to cordyceps mushroom in Chinese medicine made it interesting to investigate and it has been studied for some time. In fact, the first scientific publication on cordycepin was in 1950. The problem was that although cordycepin was a promising drug, it was quickly degraded in the body. It can now be given with another drug to help combat this, but the side effects of the second drug are a limit to its potential use.

Dr de Moor continued: “Because of technical obstacles and people moving on to other subjects, it’s taken a long time to figure out exactly how cordycepin works on cells. With this knowledge, it will be possible to predict what types of cancers might be sensitive and what other cancer drugs it may effectively combine with. It could also lay the groundwork for the design of new cancer drugs that work on the same principle.”

The team has observed two effects on the cells: at a low dose cordycepin inhibits the uncontrolled growth and division of the cells and at high doses it stops cells from sticking together, which also inhibits growth. Both of these effects probably have the same underlying mechanism, which is that cordycepin interferes with how cells make proteins. At low doses cordycepin interferes with the production of mRNA, the molecule that gives instructions on how to assemble a protein. And at higher doses it has a direct impact on the making of proteins.

Learn about Herbs – Rhodiola and Cordyceps (video)

Sandy Hutchens loves a fresh brewed cup of green tea.

Although scientists are reluctant to endorse green tea as a cancer prevention method, evidence continues to grow regarding the chemically complex drink’s potential benefits – including results of a new randomized, controlled trial by researchers at University of Texas M. D. Anderson Cancer Center, which suggest it had some inhibiting effect in patients with a pre-malignant condition known as oral leukoplakia.

As reported in a report published online Nov 5 by Cancer Prevention Research(1), a team headed by Vassiliki Papadimitrakopoulo, MD, professor of medicine in M.D. Anderson’s Department of Thoracic/Head and Neck Medical Oncology, tested green tea extract taken orally for three months by 41 patients diagnosed with oral leukoplakia and therefore at high risk of developing oral cancer.

The patients were divided into cohorts taking either placebo or one of three different doses of green tea extract 500 mg/m2, 750 mg/m2 or 1,000 mg/m2 [mg/m2 refers to milligrams per meter squared of body mass – calculated by a formula using height and weight to reflect a person’s relative size].

The researchers assessed clinical response in oral pre-malignant lesions and found:

• 58.8% of patients at the highest doses displayed clinical response,

• Compared with 18.2% among those taking placebo.

They also observed:

• A trend toward improved histology [cell & tissue integrity],

• And a trend towards improvement in a handful of biomarkers that may be important in predicting cancer development.

Patients were followed for 27.5 months and at the end of the study period, 15 developed oral cancer.

• Although there was no difference in oral cancer development overall between those who took green tea and those who did not,

• Patients who presented with mild to moderate dysplasia [abnormal cell growth] had a longer time to develop oral cancer if they took green tea extract.

Although encouraged by the results, Dr. Papadimitrakopoulo cautioned against any recommendations that green tea could definitely prevent cancer.

“This is a phase II study with a very limited number of patients who took what would be the equivalent of drinking eight to 10 cups of green tea every single day,” she said. “We cannot with certainty claim prevention benefits from a trial this size.”

Dong Shin, MD, (professor of hematology and medical oncology at Emory School of Medicine, and a Cancer Prevention Research editorial board member) agreed, but said this trial is certainly a step in the right direction. “A clinical trial with a natural compound is no easy task, and these researchers have accomplished that,” Dr. Shin stated in a companion article commenting on the trial(2). “The lack of toxicity is also important because often when you give supplements at higher doses than what would occur naturally, you induce nausea and vomiting. That did not happen in this trial.”

Neither researcher had a reason why patients concerned about cancer should not drink green tea, but they cautioned against relying on the beverage to definitively reduce their risk of cancer.

“The goal of this kind of research is to determine whether or not these supplements have long-term prevention effects,” said Dr. Papadimitrakopoulou. “More research – including studies in which individuals at high risk are exposed to these supplements for longer time period – is still needed to answer that sort of question.”